Drug – bio-affecting and body treating compositions – In vivo diagnosis or in vivo testing – Magnetic imaging agent
Reexamination Certificate
1999-12-01
2001-05-22
Jones, Dameron L. (Department: 1619)
Drug, bio-affecting and body treating compositions
In vivo diagnosis or in vivo testing
Magnetic imaging agent
C424S009300, C534S014000, C534S015000
Reexamination Certificate
active
06235264
ABSTRACT:
BACKGROUND OF THE INVENTION
This invention relates to nuclear magnetic resonance imaging (MRI) methods and systems and, particularly, to magnetic resonance imaging of tumors using contrast agents.
Tumor angiogenesis is the recruitment of new blood vessels by a growing tumor from existing neighboring vessels. This recruitment of new microvasculature is a central process in tumor growth and in the potential for aggressive spreading of the tumor through metastasis. All solid tumors require angiogenesis for growth and metastasis. Thus, the level of angiogenesis is thought to be an important parameter for the staging of tumors. Furthermore, new therapies are being developed which attack the process of angiogenesis for the purpose of attempting to control tumor growth and tumor spread by restricting or eliminating the tumor blood supply. It is therefore of clinical importance to be able to monitor angiogenesis in tumors in a noninvasive manner.
To assess angiogenic activity of tumors, two parameters are of primary importance: vascular volume and vascular permeability. Invasive techniques utilizing tissue staining can be used to assess microvascular development, but the sensitivity of existing staining methods is not high enough and the prognostic value of such methods is not yet well established (N. Weidner, et al.,
New Eng. J. Med.
324:1-8, 1991). At present there is no single imaging method capable of providing quantitative characterization of tumor angiogenesis.
As for non-invasive methods for assessing the two parameters, there is at present no accepted clinical imaging method for characterizing tumor angiogenesis. (Passe, et al.,
Radiology
203:593-600, 1997). The present invention involves a magnetic resonance imaging method with a type of contrast agent that enables measurement of both vascular volume and vascular permeability with much higher sensitivity than heretofore possible. Such measurement should facilitate independent prognostic assessments of cancer and help in monitoring cancer therapy non-invasively.
When a substance such as living tissue is subjected to a uniform magnetic field (polarizing field B
0
), individual magnetic moments of the nuclear spins in the tissue attempt to align with this polarizing field along the z axis of a Cartesian coordinate system, but precess about the z axis direction in random order at their characteristic Larmor frequency. If the substance, or tissue, is subjected to a magnetic field (excitation field B
1
) which is in the x-y plane and at a frequency near the Larmor frequency, the net aligned longitudinal magnetization may be rotated, or “tipped”, into the x-y plane to produce a net transverse magnetization. A signal is emitted by the excited spins after the excitation signal B
1
is terminated. This NMR signal may be received and processed to form an image.
When utilizing NMR signals of this type to produce images, magnetic field gradients (G
x
G
y
and G
z
) are employed. Typically, the region to be imaged is scanned with a series of measurement cycles in which these gradients vary according to the particular localization method being used. The resulting set of received NMR signals is digitized and processed to reconstruct the image using one of many well known reconstruction techniques.
One of the mechanisms employed in MRI to provide contrast in reconstructed images is the T
1
relaxation time of the spins. After excitation, a period of time is required for the longitudinal magnetization to fully recover. This period, referred to as the T
1
relaxation time, varies in length depending on the particular spin species being imaged. Spin magnetizations with shorter T
1
relaxation times appear brighter in MR images acquired using fast, T
1
weighted NMR measurement cycles. A number of contrast agents which reduce the T
1
relaxation time of neighboring water protons are used as in vivo markers in MR images. The level of signal brightness, i.e., signal enhancement, in T
1
weighted images is proportional to the concentration of the agents in the tissue being observed.
In pre-clinical research applications, high-field MRI has been used to assess tumor volume and tumor signal changes in animal models after treatment with tamoxifen, a type of antiangiogenic agent (H. E. Maretzek, et al.,
Cancer Res.,
54:5511-5514, 1994). By using an intravascular contrast agent, albumin-Gd-DTPA, tumor vascular volume and permeability were measured as well as spatial distribution of the neovasculature. In another study using a high polarizing field, tumor growth was followed by using a variety of NMR measurement pulse sequences that allowed the investigators to distinguish microvessels from larger vessels through blood oxygen level dependent effects. Permeability was assessed by noting the time dependent changes in NMR signal when Gd-DTPA was administered to the animal (R. Abramovitch, et al.,
Cancer Res.
55:1956-1962,1995).
At lower polarizing fields that are available at clinical sites, Gd-DTPA, an MRI contrast agent approved by the FDA (U.S. Food and Drug Administration) has been used to estimate angiogenic activity of tumors (C. Frouge, et al.,
Invest. Radiol.
29:1043-1049, 1994). However, this contrast agent is not ideal for characterizing tumor vasculature because it rapidly migrates to the extravascular space before being excreted through the kidneys. The tumor NMR signal measurements become delicate, being based on the dynamics of contrast agent uptake and elimination. Staging of tumors by this approach has been difficult (R. Brasch, et al.,
Radiology
200:639-649,1996).
To avoid the delicate dynamic aspects of Gd-DTPA uptake measurements, others have used a macromolecular contrast agent, albumin—Gd-DTPA (F. Demser, et al.,
Mag. Res. Med.
37:236-242, 1997). In this instance, the elimination process does not play a role in the observed MR signals, so that a much simpler and more reliable signal analysis is possible. Thus, MR signals based on T
1
changes (proportional to agent concentration) have provided indications of tumor blood vessel leak rate and tumor blood volume. This then represents an effective imaging method for assessing tumor angiogenesis. There are however, several drawback to this approach. Permeability of tumor vasculature to such macromolecules is not high enough to produce large MR signal changes, thus limiting the sensitivity of this approach. The observable MR signal changes appear to be concentrated mainly at the rim of implanted tumors and a full volume assessment appears to be lacking. However, the most serious obstacle to implementation of this approach is that this macromolecular agent has associated immune reactions when injected and leads to substantial toxicities. Thus, at present, this contrast agent is unsuitable for clinical applications (T. J. Passe, et al.,
Radiology
230:593-600,1997).
BRIEF SUMMARY OF THE INVENTION
In a preferred embodiment of the invention, tumor angiogenesis is characterized by imaging tumors using a reptating polymer contrast agent. The reptating polymer contrast agent is introduced into the subject, and magnetic resonance images of a tumor in the subject are acquired. The initial increase in image enhancement immediately following induction of the contrast agent is a measure of the blood volume and the slow rate of change in image contrast thereafter is a measure of tumor vasculature permeability.
REFERENCES:
patent: 5554748 (1996-09-01), Sieving et al.
patent: 5762909 (1998-06-01), Uzgiris
patent: 5958372 (1999-09-01), Ladd
Theodore J. Passe, M.D. et al., Tumor Angiogensis: Tutorial On Implications For Imaging, RSNA, 1997; 203: 593-600.
R. Abramovitch et al., Noevasculariztion Induced Growth Of Implanted c6 Glioma multicellular spheroids: Magnetic Resonance Microimaging, Cancer Research 55, 1956-1962, May 1, 1995.
C. Frouge et al., Correlation Between contrast Enhancement In Dymanic Magnetic Resonance Imaging Of The Breast And TumoSr Angiogenesis, Investigative Radiology, vol. 29, Nov. 12, 1994, 1043-1049.
R. Brasch, M.D. et al., Assessing Tumor Angiogenesis Using Macromole
Breedlove Jill M.
General Electric Company
Jones Dameron L.
Stoner Douglas E.
LandOfFree
Medical imaging method for characterizing tumor angiogenesis... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Medical imaging method for characterizing tumor angiogenesis..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Medical imaging method for characterizing tumor angiogenesis... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2464625